DT&CRO CO., Ltd. (KOSDAQ:383930)

Market Cap	39.50B -57.4%
Revenue (ttm)	44.36B +76.7%
Net Income	4.17B
EPS	-95.20
Shares Out	12.78M
PE Ratio	9.47
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,268
Average Volume	153,723
Open	3,125.00
Previous Close	3,130.00
Day's Range	3,060.00 - 3,200.00
52-Week Range	2,250.00 - 9,370.00
Beta	2.32
RSI	60.30
Earnings Date	n/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin, South Korea.

• Industry: Commercial Physical and Biological Research
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 383930

Financial Performance

In 2024, DT&CRO CO.'s revenue was 35.97 billion, an increase of 35.30% compared to the previous year's 26.59 billion. Losses were -2.00 billion, -87.98% less than in 2023.